ZAI Lab Acquires China Rights to Hanmi Lung Cancer Drug

Shanghai's ZAI Lab in-licensed China rights to a lung cancer drug candidate discovered by Hanmi Pharma of Korea. The molecule, HM61713, is a novel, third-generation, irreversible EGFR tyrosine kinase inhibitor that targets tumors with T790M mutations. Earlier this year, Hanmi out-licensed global rights for HM61713 to Boehringer Ingelheim in a $730 million deal, keeping rights to China and South Korea. Financial details of the agreement between ZAI and Hanmi were not disclosed. ZAI specializes in novel drugs for immunology and oncology indications. More details.... Stock Symbol: (KRX: 128940) Share this with colleagues: // //